Optimization and efficacy study of synergistic vincristine coloaded liposomal doxorubicin against breast and lung cancer.

Abstract

Aim: To improve the efficacy of poly-ethylene glycol (PEG)ylated liposomes coloaded with doxorubicin and vincristine against triple-negative breast cancer (TNBC) and non-small-cell lung cancer (NSCLC). Methods: The combinatorial index of the drugs was established using the Chou-Talalay method in MDA-MB-231 and A549 cell lines. The most effective ratio was co-encapsulated in factorial design optimized nanoliposomes which were characterized for similarity to clinical standard and evaluated in vitro and in vivo for therapeutic efficacy. Results & conclusion: The formulation exhibited more than 95% co-encapsulation, a size of 95.74 ± 2.65 nm and zeta potential of -9.17 ± 1.19 mV while having no significant differences in physicochemical and biochemical characteristics as compared with the clinical standard. Efficacy evaluation studies showed significantly improved cytotoxicity and tumor regression compared with liposomal doxorubicin indicating improvement in efficacy against TNBC and NSCLC.

• Authors: Saikat Ghosh, Rohan Lalani, Kuntal Maiti, Shubhadeep Banerjee, Vivek Patel, Subhas Bhowmick, Ambikanandan Misra
• Journal: Nanomedicine (London, England) (Nanomedicine (Lond)) Vol. 15 Issue 26 Pg. 2585-2607 (11 2020) ISSN: 1748-6963 [Electronic] England
• PMID: 33090073 (Publication Type: Journal Article)

Chemical References

• Liposomes
• liposomal doxorubicin
• Polyethylene Glycols
• Vincristine
• Doxorubicin

Topics

• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Cell Line, Tumor
• Doxorubicin (analogs & derivatives)
• Humans
• Liposomes
• Lung Neoplasms (drug therapy)
• Polyethylene Glycols
• Vincristine